Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biocon Chairwoman Kiran Mazumdar Shaw On Global Biosimilar Regulations, Partnerships And Future Competition: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

Biocon Chairwoman Kiran Mazumdar Shaw has been the face of the emerging Indian biotechnology industry for decades. Under Shaw's leadership, what started in Bangalore in 1978 as a small enzyme-manufacturing unit has transformed now into a promising enterprise with partnerships with large global companies like Bristol Myers-Squibb, Pfizer and Mylan. Shaw is known for her relentless pursuit to bring out cost-effective biopharma solutions and expresses optimism about the future of biosimilars. Fresh off a deal with Pfizer for insulins, Shaw spoke at length with PharmAsia News' India Bureau about the global opportunity and regulatory challenges for biosimilars and Biocon's recent dealmaking with Mylan and Pfizer.

You may also be interested in...



Biocon Chairperson Kiran Mazumdar Shaw On Global Biosimilar Regulations, Partnerships And Future Competition: An Interview With PharmAsia News (Part 2 of 2)

Biocon Chairwoman Kiran Mazumdar Shaw has been the face of the emerging Indian biotechnology industry for decades. Under Shaw's leadership, what started in Bangalore in 1978 as a small enzyme-manufacturing unit has transformed now into a promising enterprise with partnerships with large global companies like Bristol Myers-Squibb, Pfizer and Mylan. Shaw is known for her relentless pursuit to bring out cost-effective biopharma solutions and expresses optimism about the future of biosimilars. Fresh off a deal with Pfizer for insulins, Shaw spoke at length with PharmAsia News' India Bureau about the global opportunity and Biocon's recent dealmaking with Mylan and Pfizer in part one of this interview. In this second part, she discusses the regulatory challenges for biosimilars.

Biocon Chairperson Kiran Mazumdar Shaw On Global Biosimilar Regulations, Partnerships And Future Competition: An Interview With PharmAsia News (Part 2 of 2)

Biocon Chairwoman Kiran Mazumdar Shaw has been the face of the emerging Indian biotechnology industry for decades. Under Shaw's leadership, what started in Bangalore in 1978 as a small enzyme-manufacturing unit has transformed now into a promising enterprise with partnerships with large global companies like Bristol Myers-Squibb, Pfizer and Mylan. Shaw is known for her relentless pursuit to bring out cost-effective biopharma solutions and expresses optimism about the future of biosimilars. Fresh off a deal with Pfizer for insulins, Shaw spoke at length with PharmAsia News' India Bureau about the global opportunity and Biocon's recent dealmaking with Mylan and Pfizer in part one of this interview. In this second part, she discusses the regulatory challenges for biosimilars.

With Biocon Deal, Pfizer Expects To Gain First Mover Advantage In Global Biosimilar Insulin Market

MUMBAI - Months of widespread speculation over a likely deal between Pfizer and India's biotechnology flag-bearer Biocon finally came true as the two companies announced a comprehensive global commercialization pact to bring to market a range of insulins including analogs like glargine, aspart and lispro

Latest Headlines
See All
UsernamePublicRestriction

Register

SC073598

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel